Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INBX Inhibrx Biosciences	$15.21 +4.2%	$12.65	$10.80 ▼ $17.79	$211.35M	N/A	104,110 shs	53,361 shs
MNPR Monopar Therapeutics	$33.00 -3.2%	$37.32	$1.72 ▼ $54.30	$208.53M	0.99	358,270 shs	15,170 shs
OSTX OS Therapies	$1.82 +1.7%	$1.71	$1.12 ▼ $7.00	$51.14M	N/A	462,423 shs	145,756 shs
SCPH scPharmaceuticals	$3.92 -1.8%	$3.10	$1.94 ▼ $5.65	$210.64M	0.36	370,095 shs	140,104 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INBX Inhibrx Biosciences	+4.18%	+3.61%	+21.97%	+7.87%	+4.39%
MNPR Monopar Therapeutics	-3.23%	-4.76%	-10.57%	-26.24%	+698.07%
OSTX OS Therapies	+1.68%	-3.70%	+14.47%	+14.47%	+181,999,900.00%
SCPH scPharmaceuticals	-1.75%	-3.92%	+11.36%	+30.23%	-1.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INBX Inhibrx Biosciences	2.4795 of 5 stars	0.0	3.0	4.6	0.0	2.5	1.3
MNPR Monopar Therapeutics	2.9538 of 5 stars	3.4	5.0	0.0	0.0	2.5	0.0
OSTX OS Therapies	1.9538 of 5 stars	3.7	0.0	0.0	0.6	1.7	0.6
SCPH scPharmaceuticals	4.1437 of 5 stars	3.5	4.0	4.2	1.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
MNPR Monopar Therapeutics	2.75	Moderate Buy	$55.33	67.68% Upside
OSTX OS Therapies	3.40	Buy	$18.00	889.01% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	257.14% Upside

Current Analyst Ratings Breakdown

Latest OSTX, INBX, SCPH, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/15/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/2/2025	OSTX OS Therapies	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/31/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/20/2025	SCPH scPharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $12.00
3/20/2025	SCPH scPharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INBX Inhibrx Biosciences	$200K	1,101.20	$117.00 per share	0.13	$9.23 per share	1.65
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	$36.33M	5.70	N/A	N/A	$0.27 per share	14.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INBX Inhibrx Biosciences	$1.69B	$116.75	0.13	N/A	N/A	N/A	-85.12%	-58.90%	8/12/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
SCPH scPharmaceuticals	-$85.15M	-$1.91	N/A	N/A	N/A	-216.24%	-594.07%	-73.54%	8/13/2025 (Estimated)

Latest OSTX, INBX, SCPH, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/14/2025	Q1 2025	SCPH scPharmaceuticals	-$0.28	-$0.34	-$0.06	-$0.37	$11.63 million	$11.75 million
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A
3/19/2025	Q4 2024	SCPH scPharmaceuticals	-$0.40	-$0.35	+$0.05	-$0.35	$12.08 million	$12.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INBX Inhibrx Biosciences	1.04	5.12	5.12
MNPR Monopar Therapeutics	N/A	36.91	36.91
OSTX OS Therapies	N/A	0.76	0.76
SCPH scPharmaceuticals	3.86	5.48	4.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INBX Inhibrx Biosciences	82.46%
MNPR Monopar Therapeutics	1.83%
OSTX OS Therapies	N/A
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
INBX Inhibrx Biosciences	17.09%
MNPR Monopar Therapeutics	20.50%
OSTX OS Therapies	13.80%
SCPH scPharmaceuticals	4.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INBX Inhibrx Biosciences	166	14.48 million	12.00 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A
SCPH scPharmaceuticals	30	52.79 million	50.27 million	Optionable

OSTX, INBX, SCPH, and MNPR Headlines

Recent News About These Companies

With 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interest

June 12, 2025 | finance.yahoo.com

Nuveen Asset Management LLC Has $320,000 Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

June 6, 2025 | marketbeat.com

BNP Paribas Financial Markets Increases Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 29, 2025 | marketbeat.com

Woodline Partners LP Sells 203,808 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

May 28, 2025 | marketbeat.com

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

May 22, 2025 | seekingalpha.com

Stonepine Capital Management LLC Has $2.42 Million Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 20, 2025 | marketbeat.com

Leerink Partnrs Analysts Lower Earnings Estimates for SCPH

May 20, 2025 | marketbeat.com

Suvretta Capital Management LLC Reduces Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 19, 2025 | marketbeat.com

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 16, 2025 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.com

scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2025 | zacks.com

scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | globenewswire.com

Insights Ahead: scPharmaceuticals's Quarterly Earnings

May 13, 2025 | benzinga.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 5.24%

May 7, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, INBX, SCPH, and MNPR Company Descriptions

Inhibrx Biosciences NASDAQ:INBX

$15.21 +0.61 (+4.18%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$15.25 +0.04 (+0.26%)

As of 06/18/2025 07:09 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Monopar Therapeutics NASDAQ:MNPR

$33.00 -1.10 (-3.23%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$33.45 +0.45 (+1.36%)

As of 06/18/2025 04:04 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

OS Therapies NYSE:OSTX

$1.82 +0.03 (+1.68%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.86 +0.04 (+2.47%)

As of 06/18/2025 08:00 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

scPharmaceuticals NASDAQ:SCPH

$3.92 -0.07 (-1.75%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.85 -0.07 (-1.79%)

As of 06/18/2025 06:40 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time